The human EGF receptor as a target for cancer therapy: six new rat mAbs against the receptor on the breast carcinoma MDA-MB 468
1993
New Antibodies Targeting the Human EGF Receptor in Breast Cancer
publication
Evidence: moderate
Author Information
Author(s): H. Modjtahedi, J.M. Styles, C.J. Dean
Primary Institution: Institute of Cancer Research
Hypothesis
Can new rat monoclonal antibodies against the human EGF receptor be effective for cancer therapy?
Conclusion
The study found that the new antibodies can inhibit the growth of human tumors that overexpress the EGF receptor.
Supporting Evidence
- The antibodies inhibited the growth of several human tumor cell lines that overexpress the EGF receptor.
- Three of the antibodies were of the IgG2b isotype, which is effective in activating human immune responses.
- The antibodies did not cross-react with the c-erbB-2 proto-oncogene product.
Takeaway
Scientists created new antibodies that can stop cancer cells from growing by blocking a special receptor they need.
Methodology
The study involved producing rat monoclonal antibodies against the EGF receptor and testing their effects on various human tumor cell lines.
Limitations
The antibodies were less effective on certain tumor cell lines that secrete truncated forms of the receptor.
Want to read the original?
Access the complete publication on the publisher's website